Posts Tagged Jp Morgan
Life Science and Investment Partnership Opportunities with China – 2015 OneMed Forum & OneMed China Forum
Posted by Darshana V. Nadkarni, Ph.D. in Big Data -Cloud -IoT-Software -Mobile -Entrepreneurship, Biotech - Medical Device - Life Science - Healthcare on January 21, 2015
Opportunities and challenges for life science companies, in working with China, was a big focus of OneMed Forum, 2015. OneMed Forum 2015, took place at the same time JP Morgan event was happening in San Francisco.
The OneMed Forum conference with a mission to bring healthcare companies and investors together, opened on January 12, 2015 with a panel that discussed Opportunities in China. China has seen a very rapid economic growth that has spurred tremendous interest in investing in promising products and technologies, particularly in the healthcare arena. This panel explored strategies to access the Chinese market. There was a lot of stress on getting local partners early on. The panel also discussed deal structure alternatives for companies looking to secure capital, as well as licensing and distribution opportunities in China. (PS – please see link http://bit.ly/Zcwxqi for Life Science job opportunities in China)
After OneMed Conference ended on January, 13th, OneMedChina conference occurred at the same venue. After the opening remarks by Tony Chu, Founder and Partner with The Pharma Partners, a panel discussed a topic of great general interest “Investing in America”. It is no more that American companies are chasing Chinese investors, but also many Chinese investors are actively seeking investment opportunities in North America and Europe, particularly in the healthcare arena. There is a great deal of interest among Chinese investors in technologies that would address Chinese and global markets. The panel of experts included, Mr. Kevin Chen, Partner and Head of Healthcare Investment, Sequoia Capital China, Mr. Xiangyu Ouyang, Partner & Head of Healthcare Investment, Legend Capital, Dr. David Wang, Partner, OrbiMed China and Mr. Edward Zhou, Partner and Head of Healthcare Investment, New Horizon Capital. The panel shared insights on investment strategy to follow and shared their current global investment focus.
Next panel on “How to build a successful partnership with a Chinese company” was represented by Dr. Sanuj Ravindran, Global Head of Business Ventures, The Medicine Company and Mr. Andrew Wong, VP of Business Development at SciClone Corporation. Both panelists stressed the need for local partners. Wong said that hiring a local advisor will help bridge the culture gap. Ravindran stressed the need to get on the ground and spend some time to get business and cultural understanding for such partnership to get off to a good start.
These panels were followed by lunch with extended networking time. Rooms for one on one discussions between investors and companies were also available.
Posted by Darshana V. Nadkarni, Ph.D. in Biotech - Medical Device - Life Science - Healthcare on January 20, 2014
There was a general atmosphere of cautious optimism at 32nd Annual J.P. Morgan Healthcare Conference, in San Francisco, this year. In his opening remarks, Doug Braunstein, Vice Chairman of JP Morgan Chase & Co., welcomed 432 companies presenting at the conference plus over 9,200 attendees. This year, the presenting companies included 100 not for profit companies and 38 companies from emerging markets. Braunstein remarked that while life expectancy in the US has not improved significantly, US spends considerably more on healthcare than majority of the other nations. Increasing pressure to contain costs in healthcare represents both a major challenge for healthcare professionals, as well as a big opportunity, said Braunstein. He also remarked that healthcare industry is returning to pre-recession levels. There were 46 IPOs and over $10 million dollars were raised by life science companies, in 2013. This past year has also been a robust year in debt markets, said Braunstein. By all indications, 2014 will continue to be a robust year, and acquirers will be rewarded, in the stock market, observed Braunstein. Acquisition of Life Technologies by Thermo Fisher Scientific for $13.6 Billion was the largest acquisition deal in 2013 and is poised to give Thermo Fisher a leading position in the genetic sequencing market.